Clinical Trial Update: A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated GLPG2222 in cystic fibrosis patients who are already treated with ivacaftor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• GLPG2222
• Ivacaftor (ivacaftor)

Snippet

Sponsor: Galapagos NV | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED